Effect of intravitreal VEGF inhibitors on renal-related adverse events in patients with diabetes mellitus: systematic review and meta-analysis.

ABSTRACT:

Background

Intravitreal vascular endothelial growth factor inhibitors (VEGFis) are a standard treatment for diabetic eye complications. However, concerns persist regarding their potential nephrotoxic effects in patients with diabetes mellitus (DM), who are inherently at increased risk of renal disease due to diabetes-related microvascular damage.

Methods

We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) evaluating renal-related adverse events in DM adults receiving intravitreal VEGFis versus controls. The primary outcome was occurrence of acute kidney injury (AKI), and the secondary outcome was the risk of chronic kidney disease (CKD). Fixed-effects models pooled odds ratios (ORs) with 95% confidence intervals (CIs

SUBMITTER: Zheng Y 

PROVIDER: S-EPMC12660107 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature